Inovio Discloses $48.4M Quarter-End Cash as It Launches Underwritten Offering
INO has more than doubled off its 52-week low of $0.563.
Summary
Inovio disclosed preliminary quarter-end cash of about $48.4 million while running a same-day underwritten common stock offering whose size and price are not yet set.
Key Events · Financing and Capital Events · INO
-
Preliminary Q3 Cash of $48.4M
Inovio estimates cash, cash equivalents and short-term investments of approximately $48.4 million as of September 30, 2026, based on preliminary unaudited management estimates not reviewed by Ernst & Young.
-
Underwritten Offering Terms Still Blank
The same-day prospectus supplement covers an underwritten common stock offering led by Jefferies and Piper Sandler, with share count and public offering price left unset, so dilution cannot yet be calculated.
-
Going-Concern Backdrop
The offering follows a previously disclosed going-concern warning and cash runway into late Q1 2027, making this raise a funding necessity rather than opportunistic capital.
-
Post-Approval Timing
The raise comes days after FDA accelerated approval of VOCERYQ (INO-3107), Inovio's first approved product, disclosed in the November 2, 2026 8-K.
Analysis · INO · Life Sciences
Why this matters: Inovio is selling equity now, and this 8-K supplies the liquidity picture behind the raise. The company reports roughly $48.4 million of cash, equivalents and short-term investments at September 30, 2026. That balance is thin against a going-concern warning previously disclosed in the Q2 10-Q, which explains the timing of the offering days after winning FDA accelerated approval for VOCERYQ. The cash figure is preliminary and unaudited, and the offering's size and price are still blank, so the actual dilution is not yet knowable — but new buyers are being asked to fund the launch of the company's first approved product.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INO was trading at $1.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $149.9M. The 52-week trading range was $0.56 to $2.72. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.